BioSpace News Archive

Former SVP and Global R&D Head at Roche brings drug development experience as Rheos product engine generates medicines for immune-mediated diseases

RegeneRx Biopharmaceuticals, Inc., (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the recommended INN (International Nonproprietary Name) for Thymosin Beta 4 is timbetasin, as published by the World Health Organization (WHO).

Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain (the “Company”), announced today that it will present updated safety and efficacy data of CNTX-4975, the Company’s lead therapeutic candidate, at the 12th Annual PAINWeek National Conference

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will present initial clinical data for ARO-HBV, the company’s third generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a potentially curative therapy for patients with chronic hepatitis B virus (HBV) infection,

Second year medical students with an established track record of community leadership, superior communication skills and demonstrated interest in advancing knowledge are recognized today with the Canadian Medical Hall of Fame (CMHF) Award

Bloom Science and Biose industrie announced today an agreement for the manufacture development of Bloom Science’s novel epilepsy Live Biotherapeutic Product (LBP).

Community LIFE, an all-inclusive program empowering older adults to remain at home, is opening a thirteen thousand square-foot Health and Wellness Center in Bedford County in early September, 2018.

SiteOne Therapeutics today announced the appointment of John Hunter, Ph.D., as Chief Scientific Officer.

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that two poster presentations featuring clinical data sets using its Target Selector™ liquid biopsy platform will be presented at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer.

DZS Clinical Services today announced that it has been acquired by WDB Medical Data, Inc.